Stock Analiz

Biomerica Inc. BMRA

Biotechnology: In Vitro & In Vivo Diagnostic Substances · data as of November 13, 2026

$1.36Market cap $6M
Open the interactive analysis →

Biomerica Inc. (BMRA) is a healthcare company listed in the US with a market value of about $6M. In the twelve months to August 31, 2026 it had revenue of $4M and net income of -$5M, a net margin of -115.5%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -9% a year, a 5-year average ROIC of -66%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 92% below the current price.

About Biomerica

Biomerica is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances. Revenue went from $5M in 2015 to $4M in 2026, a decline of about 1.0% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 65% over three years (dilution for shareholders). It spends 18% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.4
P/B1.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−92%

Growth and quality

Revenue growth (1 yr)-16.2%
Revenue growth (5 yrs, per year)-9.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-89.3%
ROIC (5-yr avg.)-66.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$4M$4M$5M$5M$5M$19M$7M$7M$5M$6M$6M
Net income-$5M-$4M-$5M-$6M-$7M-$5M-$7M-$3M-$2M-$1M-$908561
Free cash flow———-$5M-$6M-$536000-$5M-$4M-$2M-$1M-$818943
EPS (diluted)$-1.64$-1.30$-2.16$-2.84$-4.00$-2.88$-4.96$-2.08$-2.08$-1.36$-0.88
Net margin-115.5%-84.8%-93.6%-110.4%-133.7%-24.0%-103.4%-40.0%-46.0%-26.3%-15.7%
ROIC—-93.1%-88.9%-68.2%-44.6%-36.9%-54.6%-13.5%-47.9%-27.1%-16.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Biomerica stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 92% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Biomerica pay a dividend?

Not currently.

Is Biomerica a good stock to buy?

We do not give buy or sell advice. Biomerica scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.